Crucial US Expert Group to Vote on Altering Newborn Hepatitis B Vaccine Guideline
Following a postponement and a remarkably divisive gathering, a national immunization advisory committee was scheduled to decide on Friday regarding a potential change to the enduring advisory that all newborns be inoculated against hepatitis B.
Fiery Exchange and a Delayed Ballot
The initial day of the conference on Thursday was characterized by fiery discussion over limiting availability to the hepatitis B vaccine for babies and a choice to postpone the decision by a day to allow panelists additional time to review the wording. The panel, which advises the CDC on immunization practices, had previously delayed on two occasions.
“Is there any definitive data of harm of giving this immunization before 30 days? Or is this speculation?” questioned one panel member.
In response, another member stated, “There is limited evidence about the long-term risk.”
Present Protocol and Likely Ramifications
The vaccine is currently suggested for each baby within 24 hours of being born to stop transmission of hepatitis B, which can result in serious liver damage. It has been administered to more than a billion persons for more than three decades.
The meeting in Atlanta provided no fresh data of injuries resulting from the vaccine. Authorities state any change to the present hepatitis B vaccination schedule could have major and extensive implications for infant and child health in the United States.
Panel Composition and Recent Changes
The advisory panel can only make recommendations to the leader of the CDC. The panel's membership has seen shifts this week, with the statement that the panel's latest chairman would depart for an agency job and be replaced by a heart specialist who has been skeptical about other immunizations.
The board includes several vaccine skeptics who are in agreement with a aim to revamp – and potentially, in some cases, scrap – longstanding immunization guidelines.
